Karlsson Linnea, Zickert Agneta, Svenungsson Elisabet, Schmidt-Mende Jan, Faustini Francesca, Gunnarsson Iva
Department of Medicine, Division of Rheumatology, Karolinska Institutet, Solna, Sweden.
Rheumatology, Karolinska University Hospital, Stockholm, Sweden.
Clin Rheumatol. 2023 Nov;42(11):2981-2986. doi: 10.1007/s10067-023-06682-w. Epub 2023 Jul 13.
Kidney biopsy is the reference tool for diagnosing and guiding treatment strategies in inflammatory renal diseases, such as lupus nephritis (LN). We investigated the histopathological findings in first-time kidney biopsies from a large cohort of SLE patients. We focused on the occurrence and type of histopathological findings other than LN, and fulfillment of renal criteria in established SLE classification systems were analyzed.
We retrospectively included SLE patients (n = 139) who underwent a first kidney biopsy between 1995 and 2021, upon clinical suspicion of renal involvement. Based on histology, two groups were defined, LN and non-LN, for which clinical and laboratory features were compared.
Findings consistent with LN according to ISN/RPS classification system were present in 123/139 patients (88.5%) and findings not consistent with LN were present in 16 /139 (11.5%). Non-LN patients were older at SLE diagnosis compared to LN patients (M, years 38.0 vs. 30.1, p=0.013) and had longer disease duration (M, years 11.9 vs 0.5) (p=0.027). Among non-LN patients 85.7% met the SLICC criteria item for renal SLE, seen in 94.7% in the LN group (ns). For the ACR/EULAR criteria, 66.7% of the non-LN group fulfilled the criteria compared to 74.8% in LN patients (ns). Proteinuria below the criteria cut-off level (< 0.5 g/24 h) was seen in 20% of patients with class III/IV LN.
Our data confirm the importance of kidney biopsy for ruling out the presence of renal pathology other than LN. Patients with low-grade proteinuria may exhibit severe types of LN, which reinforces the need for early biopsies to detect LN. Key Points • Our findings show that histopathology changes other than lupus nephritis may occur in a significant number of patients with clinical and laboratory signs of novel kidney involvement. • Low-grade proteinuria does not exclude findings of active lupus nephritis that require the start of immunosuppressive therapy. • The study stresses the importance of performing kidney biopsies also in the presence of low-grade proteinuria or when signs of kidney function abnormalities occur. • This is crucial as early detection and prompt initiation of therapy may improve outcomes in lupus nephritis.
肾活检是诊断和指导炎症性肾病(如狼疮性肾炎(LN))治疗策略的参考工具。我们研究了一大群系统性红斑狼疮(SLE)患者首次肾活检的组织病理学结果。我们关注LN以外的组织病理学结果的发生情况和类型,并分析了既定SLE分类系统中肾脏标准的满足情况。
我们回顾性纳入了1995年至2021年间因临床怀疑肾脏受累而接受首次肾活检的SLE患者(n = 139)。根据组织学定义了两组,LN组和非LN组,并比较了它们的临床和实验室特征。
根据国际肾脏病学会/肾脏病理学会(ISN/RPS)分类系统,123/139例患者(88.5%)有符合LN的表现,16/139例(11.5%)有不符合LN的表现。与LN患者相比,非LN患者SLE诊断时年龄更大(中位数,岁:38.0对30.1,p = 0.013),病程更长(中位数,岁:11.9对0.5)(p = 0.027)。非LN患者中85.7%符合肾脏SLE的SLICC标准项目,LN组为94.7%(无显著性差异)。对于美国风湿病学会/欧洲抗风湿病联盟(ACR/EULAR)标准,非LN组66.7%符合标准,LN患者为74.8%(无显著性差异)。III/IV级LN患者中有20%蛋白尿低于标准临界值(< 0.5 g/24小时)。
我们的数据证实了肾活检对于排除LN以外肾脏病理情况的重要性。轻度蛋白尿患者可能表现为严重类型的LN,这进一步强调了早期活检以检测LN的必要性。要点 • 我们的研究结果表明,在大量有新的肾脏受累临床和实验室体征的患者中,可能会出现狼疮性肾炎以外的组织病理学改变。 • 轻度蛋白尿并不能排除需要开始免疫抑制治疗的活动性狼疮性肾炎的表现。 • 该研究强调了在存在轻度蛋白尿或出现肾功能异常体征时进行肾活检的重要性。 • 这至关重要,因为早期检测和及时开始治疗可能改善狼疮性肾炎的预后。